Literature DB >> 26980160

Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum.

Timothy Hardy1, Fiona Oakley1, Quentin M Anstee1, Christopher P Day1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver dysfunction in the Western world and is increasing owing to its close association with obesity and insulin resistance. NAFLD represents a spectrum of liver disease that, in a minority of patients, can lead to progressive nonalcoholic steatohepatitis (NASH), fibrosis, and ultimately hepatocellular carcinoma and liver failure. NAFLD is a complex trait resulting from the interaction between environmental exposure and a susceptible polygenic background and comprising multiple independent modifiers of risk, such as the microbiome. The molecular mechanisms that combine to define the transition to NASH and progressive disease are complex, and consequently, no pharmacological therapy currently exists to treat NASH. A better understanding of the pathogenesis of NAFLD is critical if new treatments are to be discovered.

Entities:  

Keywords:  NAFLD; NASH; genetics; natural history; pathophysiology; steatohepatitis

Mesh:

Year:  2016        PMID: 26980160     DOI: 10.1146/annurev-pathol-012615-044224

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  151 in total

1.  Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH.

Authors:  Xiaoya Li; Jing Wang; Xue Gong; Meiling Zhang; Shuangshuang Kang; Bing Shu; Zuzhuang Wei; Zhi-Shu Huang; Ding Li
Journal:  Nucleic Acids Res       Date:  2020-09-04       Impact factor: 16.971

2.  Magnesium isoglycyrrhizinate ameliorates high fructose-induced liver fibrosis in rat by increasing miR-375-3p to suppress JAK2/STAT3 pathway and TGF-β1/Smad signaling.

Authors:  Yan-Zi Yang; Xiao-Juan Zhao; Hong-Jiang Xu; Shan-Chun Wang; Ying Pan; Shui-Juan Wang; Qiang Xu; Rui-Qing Jiao; Hong-Mei Gu; Ling-Dong Kong
Journal:  Acta Pharmacol Sin       Date:  2018-12-19       Impact factor: 6.150

3.  Regulation of lipophagy in NAFLD by cellular metabolism and CD36.

Authors:  Dmitri Samovski; Nada A Abumrad
Journal:  J Lipid Res       Date:  2019-02-28       Impact factor: 5.922

Review 4.  Endocrine-disrupting chemicals and fatty liver disease.

Authors:  Charles E Foulds; Lindsey S Treviño; Brian York; Cheryl L Walker
Journal:  Nat Rev Endocrinol       Date:  2017-05-19       Impact factor: 43.330

5.  Novel substituted pyrazolone derivatives as AMP-activated protein kinase activators to inhibit lipid synthesis and reduce lipid accumulation in ob/ob mice.

Authors:  Mei Zhang; Zhi-Fu Xie; Run-Tao Zhang; Da-Kai Chen; Min Gu; Shi-Chao Cui; Yang-Ming Zhang; Xin-Wen Zhang; Yan-Yan Yu; Jia Li; Fa-Jun Nan; Jing-Ya Li
Journal:  Acta Pharmacol Sin       Date:  2018-05-24       Impact factor: 6.150

6.  Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis.

Authors:  Jason S Seidman; Ty D Troutman; Mashito Sakai; Anita Gola; Nathanael J Spann; Hunter Bennett; Cassi M Bruni; Zhengyu Ouyang; Rick Z Li; Xiaoli Sun; BaoChau T Vu; Martina P Pasillas; Kaori M Ego; David Gosselin; Verena M Link; Ling-Wa Chong; Ronald M Evans; Bonne M Thompson; Jeffrey G McDonald; Mojgan Hosseini; Joseph L Witztum; Ronald N Germain; Christopher K Glass
Journal:  Immunity       Date:  2020-05-01       Impact factor: 31.745

7.  Arid1a Loss Drives Nonalcoholic Steatohepatitis in Mice Through Epigenetic Dysregulation of Hepatic Lipogenesis and Fatty Acid Oxidation.

Authors:  Austin Moore; Linwei Wu; Jen-Chieh Chuang; Xuxu Sun; Xin Luo; Purva Gopal; Lin Li; Cemre Celen; Michael Zimmer; Hao Zhu
Journal:  Hepatology       Date:  2019-03-18       Impact factor: 17.425

Review 8.  Endocrine Disruptors and Developmental Origins of Nonalcoholic Fatty Liver Disease.

Authors:  Lindsey S Treviño; Tiffany A Katz
Journal:  Endocrinology       Date:  2018-01-01       Impact factor: 4.736

9.  Integration of Multi-omics Data from Mouse Diversity Panel Highlights Mitochondrial Dysfunction in Non-alcoholic Fatty Liver Disease.

Authors:  Karthickeyan Chella Krishnan; Zeyneb Kurt; Rio Barrere-Cain; Simon Sabir; Aditi Das; Raquel Floyd; Laurent Vergnes; Yuqi Zhao; Nam Che; Sarada Charugundla; Hannah Qi; Zhiqiang Zhou; Yonghong Meng; Calvin Pan; Marcus M Seldin; Frode Norheim; Simon Hui; Karen Reue; Aldons J Lusis; Xia Yang
Journal:  Cell Syst       Date:  2018-01-18       Impact factor: 10.304

Review 10.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.